Literature DB >> 7070622

Structural changes in human pituitary tumor after bromocriptine therapy.

S S Rengachary, T Tomita, B F Jefferies, I Watanabe.   

Abstract

The histological appearance of a prolactin-producing tumor and of a growth hormone-producing tumor after short term bromocriptine therapy was studied in detail using light microscopy with conventional and immunocytochemical methods and using transmission electron microscopy. The findings were correlated with clinical, radiological, and biochemical data. Histological changes consisting of clumping of nuclear chromatin and a marked reduction in cytoplasmic volume due to loss of ribosomes, rough endoplasmic reticulum, and Golgi complexes were observed only in the prolactin-producing tumor. Normalization of elevated serum prolactin levels and reduction in size of the tumor observed in serial computed tomograms correlated with striking histological changes found in the tumor. These changes were interpreted to represent a reversible inhibition of the protein-synthetic machinery of the neoplastic cell. Comparable clinical, biochemical, radiological, or structural changes were not observed in the growth hormone-secreting tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7070622

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  13 in total

1.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Positron emission tomography applied in the study of pituitary adenomas.

Authors:  C Muhr; M Bergström
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

Review 4.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

5.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology.

Authors:  M Nissim; B Ambrosi; V Bernasconi; G Giannattasio; M A Giovanelli; M Bassetti; U Vaccari; P Moriondo; A Spada; P Travaglini; G Faglia
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

6.  Pituitary adenomas in patients under 20 years old. A clinicopathological study of 12 cases.

Authors:  K Mukai; E L Seljeskog; L P Dehner
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

7.  Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.

Authors:  A M Landolt; H Minder; V Osterwalder; T A Landolt
Journal:  Experientia       Date:  1983-06-15

8.  Topical effect of bromocriptine on rat-transplanted human prolactinomas.

Authors:  B Açikgöz; T Ozgen; O E Ozcan; S Ruacan; T Erbengi; M Sumnu
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

9.  Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).

Authors:  Alireza M Manuchehri; Thozhukat Sathyapalan; Martin Lowry; Lindsay W Turnbull; Christopher Rowland-Hill; Stephen L Atkin
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

10.  Effect of acrylonitrile on the rat pituitary: enlargement of Golgi region in prolactin cells, crinophagy in prolactin cells and growth hormone cells.

Authors:  K Kamijo; K Kovacs; S Szabo; J N Bollinger-Gruber; S Reichlin
Journal:  Br J Exp Pathol       Date:  1986-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.